Evidence map›Paper›PMID 37274117›Full record

ArticleFrontiers in pharmacology2023

In

Xue-Ling Yang, Chun-Xuan Wang, Jia-Xing Wang, Shi-Min Wu, Qing Yong, Ke Li, Ju-Rong Yang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Xue-Ling YangDepartment of Nephrology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Chun-Xuan WangDepartment of Nephrology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Jia-Xing WangCore Research Laboratory, The Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
Shi-Min WuBeijing Key Laboratory of Bioprocess, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China.
Qing YongCore Research Laboratory, The Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
Ke LiCore Research Laboratory, The Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
Ju-Rong YangDepartment of Nephrology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Chongqing Medical University · CNSecond Affiliated Hospital of Xi'an Jiaotong University · CNBeijing University of Chemical Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19-associated acute kidney injury (COVID-19 AKI) is an independent risk factor for in-hospital mortality and has the potential to progress to chronic kidney disease.

Indexed as

acute kidney injuryCOVID-19cytokine stormmolecular dockingnetwork pharmacology

Identifiers

PMID37274117
PMCPMC10232756
OpenAlexW4377024144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.